SAN FRANCISCO and SUZHOU, China, Feb. 21, 2022 — Innovent Biologics, Inc (HKEX: 01801) today announced the first patient dosing for its first-in-class IgG-based universal “modular” Claudin 18.2-targeting chimeric antigen receptor T (CAR-T) cell product (development code: IBI345) for the treatment of advanced Claudin18.2-positive solid tumors in an investigator-initiated-trial